Post-approval studies (Phase 4)Study completedNCT02788474
What this trial is testing
Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment
Who this might be right for
Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim 347